Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
Purpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2020/1875860 |
id |
doaj-3383bdfa7365423b9ae73f002a55f6ad |
---|---|
record_format |
Article |
spelling |
doaj-3383bdfa7365423b9ae73f002a55f6ad2020-11-25T03:03:36ZengHindawi LimitedJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/18758601875860Systemic Factors Associated with Treatment Response in Diabetic Macular EdemaWendy Meihua Wong0Caroline Chee1Mayuri Bhargava2Charmaine Chai3Hazel Lin4Paul Zhao5Erlangga Ariadarma Mangunkusumo6Thet Naing7Yew Sen Yuen8Tien Yin Wong9Xinyi Su10Gopal Lingam11National University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporePurpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change in macular thickness one month after treatment, measured using spectral-domain optical coherence tomography (OCT). At baseline, information on various systemic factors was collected including glycosylated hemoglobin (HbA1c), serum VEGF levels, lipid profile and markers of renal function, and blood pressure. Thirty-three of the 35 patients were included in this study. Nonparametric statistical tests were used for the analysis of the data in view of the nonnormal distribution of the outcome variables. Multivariate analysis was performed using logistic regression. Stata 12.1 software was used for the analysis. Main Outcome Measures. Reduction in macular central subfield thickness (on spectral-domain OCT) and change in logMAR visual acuity at one month after injection. Results. Lower HbA1c levels (7% or less) were significantly associated with greater reduction in central macular subfield thickness at one month after injection of bevacizumab or ranibizumab on both univariate analysis (p=0.012) and multivariate analysis (p=0.042). Conclusions. Better glycemic control is associated with a greater reduction in central macular thickness after the first injection of bevacizumab or ranibizumab in diabetic macular edema. Patients with high levels of HbA1c and poor response to anti-VEGF may benefit from strict control of their blood glucose.http://dx.doi.org/10.1155/2020/1875860 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wendy Meihua Wong Caroline Chee Mayuri Bhargava Charmaine Chai Hazel Lin Paul Zhao Erlangga Ariadarma Mangunkusumo Thet Naing Yew Sen Yuen Tien Yin Wong Xinyi Su Gopal Lingam |
spellingShingle |
Wendy Meihua Wong Caroline Chee Mayuri Bhargava Charmaine Chai Hazel Lin Paul Zhao Erlangga Ariadarma Mangunkusumo Thet Naing Yew Sen Yuen Tien Yin Wong Xinyi Su Gopal Lingam Systemic Factors Associated with Treatment Response in Diabetic Macular Edema Journal of Ophthalmology |
author_facet |
Wendy Meihua Wong Caroline Chee Mayuri Bhargava Charmaine Chai Hazel Lin Paul Zhao Erlangga Ariadarma Mangunkusumo Thet Naing Yew Sen Yuen Tien Yin Wong Xinyi Su Gopal Lingam |
author_sort |
Wendy Meihua Wong |
title |
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema |
title_short |
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema |
title_full |
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema |
title_fullStr |
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema |
title_full_unstemmed |
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema |
title_sort |
systemic factors associated with treatment response in diabetic macular edema |
publisher |
Hindawi Limited |
series |
Journal of Ophthalmology |
issn |
2090-004X 2090-0058 |
publishDate |
2020-01-01 |
description |
Purpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change in macular thickness one month after treatment, measured using spectral-domain optical coherence tomography (OCT). At baseline, information on various systemic factors was collected including glycosylated hemoglobin (HbA1c), serum VEGF levels, lipid profile and markers of renal function, and blood pressure. Thirty-three of the 35 patients were included in this study. Nonparametric statistical tests were used for the analysis of the data in view of the nonnormal distribution of the outcome variables. Multivariate analysis was performed using logistic regression. Stata 12.1 software was used for the analysis. Main Outcome Measures. Reduction in macular central subfield thickness (on spectral-domain OCT) and change in logMAR visual acuity at one month after injection. Results. Lower HbA1c levels (7% or less) were significantly associated with greater reduction in central macular subfield thickness at one month after injection of bevacizumab or ranibizumab on both univariate analysis (p=0.012) and multivariate analysis (p=0.042). Conclusions. Better glycemic control is associated with a greater reduction in central macular thickness after the first injection of bevacizumab or ranibizumab in diabetic macular edema. Patients with high levels of HbA1c and poor response to anti-VEGF may benefit from strict control of their blood glucose. |
url |
http://dx.doi.org/10.1155/2020/1875860 |
work_keys_str_mv |
AT wendymeihuawong systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT carolinechee systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT mayuribhargava systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT charmainechai systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT hazellin systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT paulzhao systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT erlanggaariadarmamangunkusumo systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT thetnaing systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT yewsenyuen systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT tienyinwong systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT xinyisu systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema AT gopallingam systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema |
_version_ |
1715316141058949120 |